novo nordisk fda semaglutide Novo's Ozempic wins nod to curb kidney disease risks Novo Nordisk expands patient access
Description
Purpose of Review There has been a rise in popularity and use of GLP-1 receptor agonists since their approval for obesity management

She had a large local immediate injection site reaction that appeared 15 min following an exenatide BID 5 mcg/20 mcl injection

Hanmi expects to initiate Phase 1 clinical trials for HM17321 in the second half of 2025.According to recent reports from GlobalData Patent Analytics and IFI CLAIMS Patent Services, Hanmi ranks among the global leaders in both the volume and quality of obesity drug patent filings, alongside multinational pharmaceutical companies such as Eli Lilly and Novo Nordisk.Innovation in metabolic and endocrine diseases has been a core focus for Hanmi over many years, and the ADA 2025 presentations represent a critical opportunity to showcase our global competitiveness, said Dr

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current medications in alleviating symptoms.

Current research suggests that retatrutide may lead to greater weight loss than other drugs on the market, but potentially at a high cost., Health News News, Health and Me

A food-first guide to sulfur burps on GLP-1, including what usually makes them worse, what tends to sit better, and a simple reset plan.
